Dong-E-E-Jiao's net profit soars 35.29% in 2024

China Resources Pharmaceutical Group (HKEX:3320) announced key financial information for its subsidiary Dong-E-E-Jiao Co., Ltd. for the year ended December 31, 2024. Dong-E-E-Jiao's revenue increased by 25.57% to RMB 5,920.8 million, compared to RMB 4,715.3 million in 2023. Net profit attributable to shareholders rose significantly by 35.29% to RMB 1,557.0 million, up from RMB 1,150.9 million in the previous year. Basic and diluted earnings per share both increased by 35.20% to RMB 2.42. The company's board has proposed a cash dividend of RMB 12.70 per 10 shares, subject to shareholder approval. Total assets decreased slightly by 1.65% to RMB 13,087.1 million, while net assets attributable to shareholders fell by 3.81% to RMB 10,310.2 million. The weighted average return on net assets improved to 14.60%.